Evidence map›Paper›PMID 35145816›Full record

ArticleCureus2022

Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report.

Prashant Ahlawat, Monica Gupta, Prateek Upadhyay, Shivani Gupta, Amanjot Kaur

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Prashant AhlawatGeneral Medicine, Government Medical College & Hospital, Chandigarh, IND.
Monica GuptaGeneral Medicine, Government Medical College & Hospital, Chandigarh, IND.
Prateek UpadhyayAnaesthesiology, Government Medical College & Hospital, Chandigarh, IND.
Shivani GuptaGeneral Medicine, Government Medical College & Hospital, Chandigarh, IND.
Amanjot KaurGeneral Medicine, Government Medical College & Hospital, Chandigarh, IND.
Government Medical College and Hospital · INGovernment Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine is a broad-spectrum anti-metabolite drug that is widely used in the therapy of numerous advanced cancers such as pancreatic, breast, ovary, lung, and bladder cancer. Gemcitabine has been reported to cause hemolytic uremic syndrome (HUS), but the underlying mechanism is not elucidated. The outcome of gemcitabine-induced HUS is often poor and associated with high mortality. We present a case report of a patient who was on chemotherapy for lung cancer and presented with the concerns of decreased urine output and shortness of breath. He was investigated and found to have HUS

Indexed as

chemotherapygemcitabine-induced hemolytic uremic syndromegeriatricshemolytic uremic syndromelung cancer

Identifiers

PMID35145816
PMCPMC8812056
OpenAlexW4205386783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.